Next Science Ltd (NXS)

Snapshot

NXS's Principal Activity is the research, development and commercialisation of technologies which solve issues in human health caused by biofilms.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Mr Mark Raymond Compton	Non-Executive Director,Non-Executive Chairman	Oct 2018	Mr Mark Raymond Compton Non-Executive Director,Non-Executive Chairman Mr Compton is Lord Prior of the International Order of St John and Chairman of the Board of Trustees of St John International. He is also Chairman of St Luke's Care Limited and Chairman of Integrated Clinical Oncology Network Pty Ltd trading as Icon Cancer Centre. Mark has held range of CEO and managing director roles, including at St Luke's Care Limited, Immune System Therapeutics Limited, Royal Flying Doctor Service of Australia, SciGen Limited and Alpha Healthcare Limited. He is an Adjunct Professor at Macquarie University in healthcare leadership and management (since 2012). He is a member of People, Culture Committee.
Mrs Aileen Stockburger	Non-Executive Director	Oct 2018	Mrs Aileen Stockburger Non-Executive Director Mrs Stockburger was the Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. She led Johnson & Johnson's efforts to acquire Synthes. She also led the efforts to divest the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also part of range of other M&A transactions including Pfizer Consumer Healthcare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. He is a Non-Executive Director of Microbot Medical Inc. She is a member of Risk Committee.
Ms Gillian Maria Nairn	Company Secretary	Jun 2018
Mr Bruce Alan Hancox	Non-Executive Director	Oct 2017	Mr Bruce Alan Hancox Non-Executive Director Mr Hancox has over 35 years of corporate experience across commerce, including 16 years with Brierley Investments Limited in New Zealand. He held a number of senior roles at Brierley Investments as general manager and Chairman and served on the board of a number of their subsidiaries in New Zealand, Australia and the US. Bruce has been a financial advisor to interests of Mr Langley Walker since 2008. He serves as a director of investments and wealth management at Walker Corporation Pty Ltd and works with the Walker group of companies to pursue investment opportunities outside the property market. He is a Director of Walker Group Holdings Pty Limited. He is Chair of the Risk Committee.
Mr Daniel (Dan) Spira	Non-Executive Director	Oct 2017	Mr Daniel (Dan) Spira Non-Executive Director Mr Spira is the CEO of iNova Pharmaceuticals (since 2017) which is a multinational consumer healthcare and pharmaceutical company with operations across Asia Pacific and Africa. Previously he was at Bausch Health (2011-2015) as Vice President and GM North America and was also Managing Director, Pacific region. Prior to that, Daniel spent over 15 years at Johnson & Johnson Inc in range of roles including Vice President, Country Manager, Chief Marketing Officer and other sales and marketing roles across the Asia Pacific, Europe/Middle East and North American regions. He is a Chair of People, Culture Committee.
Ms Judith Mitchell	Managing Director	Oct 2017	Ms Judith Mitchell Managing Director Ms Mitchell served as President of DePuy Synthes Asia Pacific, the Orthopaedics Division of Johnson & Johnson, before which Judith was President of Asia Pacific for Synthes GmbH. Judith commenced her medical technology career at GE Medical Systems, where over 14 years, she held positions in sales, marketing and management. She also held a range of positions at Cochlear Limited in Product Development, Global Marketing and Education.
Dustin Haines	Chief Commercial Officer	N/A
Jacqueline Butler	Chief Financial Officer	N/A
Jon Swanson	Chief Operating Officer	N/A
Matthew Myntti	Chief Technology Officer	N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
28/04/21	Daniel (Dan) Spira	Sell	+3,487	$1.71	($5,962)	As advised by the company
26/04/21	Daniel (Dan) Spira	Sell	+362,342	$1.57	($568,876)	As advised by the company
13/04/21	Daniel (Dan) Spira	Exercise	1,040,000	$0.55	$572,000	Exercise of options
13/04/21	Daniel (Dan) Spira	Buy	+1,040,000	$0.55	$572,000	Exercise of options
24/11/20	Bruce Hancox	Buy	+130,000	$1.149	$149,344	On-market trade
24/11/20	Judith Mitchell	Buy	+24,362	$1.14	$27,772	On-market trade
24/11/20	Judith Mitchell	Buy	+43,000	$1.14	$49,020	On-market trade
29/10/20	Judith Mitchell	Buy	+22,438	$1.155	$25,907	On-market trade
29/10/20	Judith Mitchell	Buy	+178,200	$1.155	$205,755	On-market trade
28/10/20	Bruce Hancox	Buy	+30,000	$1.16	$34,800	On-market trade
19/10/20	George Savvides	Buy	+24,876	$1.18	$29,353	Participation in share purchase plan
19/10/20	Mark Compton	Buy	+12,438	$1.18	$14,676	Participation in share purchase plan
19/10/20	Judith Mitchell	Buy	+12,438	$1.18	$14,676	Participation in share purchase plan
02/10/20	Bruce Hancox	Buy	+154,330	$1.24	$191,369	On-market trade
24/09/20	Bruce Hancox	Buy	+70,000	$1.24	$86,800	On-market trade
24/09/20	Bruce Hancox	Buy	+145,670	$1.206	$175,707	On-market trade
06/05/20	Aileen Stockburger	Issued	11,283	$1.99	$22,453	Director remuneration
06/05/20	Daniel (Dan) Spira	Issued	12,537	$1.99	$24,948	Director remuneration
19/12/19	Aileen Stockburger	Issued	7,977	$2.82	$22,495	Director remuneration
19/12/19	Dan Spira	Issued	8,865	$2.82	$24,999	Director remuneration
25/09/19	Dan Spira	Issued	27,864	$1.674	$46,644	Director remuneration
25/09/19	Aileen Stockburger	Issued	25,577	$1.661	$42,475	Director remuneration

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Daniel (Dan) Spira	28/04/2021	723,437	N/A	260,000	N/A
Judith Mitchell	31/12/2020	4,778,800	221,200	2,340,000	N/A
Aileen Stockburger	31/12/2020	44,837	N/A	520,000	N/A
Bruce Hancox	31/12/2020	460,000	70,000	520,000	N/A
Mark Compton	31/12/2020	N/A	137,438	520,000	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
Auckland Trust Company Ltd ATF Secord Pacific Master Superannuation Fund	56,019,938	28.85%
Walker Group Holdings Pty Limited	21,719,667	11.18%
Matthew Myntti	20,657,000	10.64%
HSBC Custody Nominees (Australia) Limited A/C 2	6,299,588	3.24%
Merrill Lynch (Australia) Nominees Pty Limited	5,130,056	2.64%
Judith Mitchell	4,744,438	2.44%
HSBC Custody Nominees (Australia) Limited	3,534,393	1.82%
UBS Nominees Pty Ltd	3,464,130	1.78%
Mr Charles Robert Dirck Wittenoom	2,825,000	1.45%
National Nominees Limited	2,443,875	1.26%
Citicorp Nominees Ply Limited	1,637,135	0.84%
Scone Investments Pty Ltd	1,159,452	0.60%
G & N Lord Superannuation Pty Ltd <GNR Superannuation Fund A/C>	965,000	0.50%
Mr Byron James Darroch	962,500	0.50%
Ka-tet Pty Ltd <The Rosenrot Trust>	890,500	0.46%
Donald Ayers	672,394	0.35%
Insync Investments Pty Ltd <Weekley Super Fund No 1 A/C>	625,000	0.32%
Authentics Australia Pty Ltd <Authentics Australia A/C>	512,438	0.26%
Tsunami Ventures Pty Ltd <Drizzle Family A/C>	500,938	0.26%
Honne Investments Pty Limited	500,000	0.26%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$1.25	30 June
2019	$4.11	28 June
2014	$0.013	30 June

NXS Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.